DNA extraction: suitable RNA extraction: suitable nuclear extraction: suitable protein extraction: suitable
input
sample type cells
shipped in
dry ice
storage temp.
−20°C
General description
Note: 1 Test = reagents sufficient for processing 5 x 107 cells.
This kit provides a unique combination of reagents useful for the isolation of a highly enriched mitochondrial fraction from the cytosol. The enriched fractions can be used to study factors of interest using Western blotting, ELISA, or other assays.
Components
Mitochondria Extraction Buffer, Cytosol Extraction Buffer, Protease Inhibitor Cocktail, Reducing Reagent, and a user protocol.
Warning
Toxicity: Multiple Toxicity Values, refer to MSDS (O)
Principle
The ProteoExtract Cytosol/Mitochondria Fractionation Kit is designed for extraction of mammalian cells to yield enriched mitochondrial and cytosolic fractions for use in downstream analyses, such as Western blotting.
Preparation Note
• Protease Inhibitor Cocktail: Reconstitute the lyophilized Protease Inhibitor Cocktail by adding 250 µl DMSO; mix well before use. Dispense into aliquots and store at -20°C.• 1X Cytosol Extraction Buffer Mix: Prepare 1X Cytosol Extraction Buffer by diluting the Cytosol Extraction Buffer 1:4 with ddH2O. Prepare only the amount needed for the assay (5 x 107 cells require 1 ml 1X Cytosol Extraction Buffer Mix). Just prior to use add 2 µl Protease Inhibitor Cocktail and 1 µl DTT to 1 ml 1X Cytosol Extraction Buffer.• Mitochondria Extraction Buffer Mix: Prepare only the amount needed for the assay (5 x 107 pelleted cells require 100 µl Mitochondria Extraction Buffer Mix). Just prior to use, add 2 µl Protease Inhibitor Cocktail and 1 µl DTT to 1 ml of Mitochondria Extraction Buffer.
Storage and Stability
Upon arrival store the entire contents of the kit at -20°C. Following initial use, store the buffers at 4°C and the DTT and Protease Inhibitor Cocktail at -20°C.
Other Notes
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
PROTEOEXTRACT is a registered trademark of Merck KGaA, Darmstadt, Germany
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 33(3), 4327-4340 (2018-12-20)
Knockdown of the suppression of tumorigenicity 14-encoding type II transmembrane serine protease matriptase (MTP) in neural stem/progenitor (NS/P) cells impairs cell mobility, response to chemo-attractants, and neurovascular niche interaction. In the present study, we showed by Western blot that a
International journal of oncology, 51(2), 563-572 (2017-06-07)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Despite improved remission rates, current treatment regimens for AML are often associated with a very poor prognosis and adverse effects, necessitating more effective and safer agents. B-cell leukemia/lymphoma 2
Human coronaviruses (HCoV) are recognized respiratory pathogens. Some HCoV strains, including HCoV-OC43, can invade the central nervous system, where they infect neurons, with unclear consequences. We have previously reported that HCoV-OC43 infection of human neurons activates the unfolded-protein response and
Locoweeds cause significant livestock poisoning and economic loss all over the world. Animals can develop locoism, a chronic neurological disease, after grazing on locoweeds. Oxytropis kansuensis is a variety of locoweed that contains swainsonine as its main toxic ingredient. The
Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of B-cell receptor
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.